Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Yuan, Deng, Biping, Rong, Luan, Li, Chuo, Song, Weiliang, Ling, Zhuojun, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Chang, Alex H., Feng, Xiaoming, Xiong, Xiujuan, Chen, Xiaoli, Pan, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279746/
https://www.ncbi.nlm.nih.gov/pubmed/34277400
http://dx.doi.org/10.3389/fonc.2021.640166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279746/
https://www.ncbi.nlm.nih.gov/pubmed/34277400
http://dx.doi.org/10.3389/fonc.2021.640166

Ejemplares similares